Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2024-02-13 Major Shareholding Noti…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-13 English
SC 13G/A
Major Shareholding Notification
2024-02-12 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 9, 2024, by Sutro Biopharma, Inc. It discusses an update related to the company's Open Market Sale Agreement and shelf registration statements for selling shares. The content focuses on capital raising activities, including the filing of a prospectus supplement to increase the amount of shares available for sale. There are no financial statements or detailed financial performance data included, but rather an update on financing and capital structure changes. This fits the definition of a Capital/Financing Update (CAP). The document length is about 4900 characters, which is sufficient to provide substantive information rather than just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2024-02-09 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement for the offering and sale of common stock. It includes detailed information about the offering, the sales agreement with Jefferies LLC, risk factors, use of proceeds, and legal matters. It references SEC registration numbers and incorporates by reference various SEC filings such as Form 10-K, 10-Q, 8-K, and proxy statements. The document is a formal offering document used to raise capital through the sale of securities. This type of document is classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising and capital structure changes through a securities offering.
2024-02-09 English
SUTRO BIOPHARMA, INC.
Major Shareholding Notification
2024-02-07 English
Director's Dealing 2024
Director's Dealing
2024-01-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.